# Galera Therapeutics, Inc. (GRTX) — merger/definitive [completed]
Source: SEC API (secapi.ai) · situation sit_376c000413480a0c2efc · retrieved 2026-08-12T21:27:10.572Z

## Overview
Galera Therapeutics, Inc. is a biopharmaceutical company developing pharmaceutical products, including tilarganine-based products and supportive-care compounds GC4419 and GC4711.

On August 3, 2026, Galera Therapeutics, Inc. completed a merger with Obsidian Therapeutics, Inc. pursuant to an Agreement and Plan of Merger dated April 14, 2026. In the transaction, Obsidian Merger Sub merged with and into Legacy Obsidian (with Legacy Obsidian surviving), and immediately thereafter Galera Merger Sub merged with and into Galera (with Galera surviving). Both companies became wholly owned subsidiaries of Obsidian Therapeutics, Inc. (formerly Gazelle Parent, Inc.). Legacy Obsidian securityholders received shares at an exchange ratio of 0.1383 and owned approximately 51.6% of the combined company on a fully diluted basis; Galera securityholders received shares at an exchange ratio of 0.7019 and owned approximately 1.2%; and concurrent PIPE investors owned approximately 47.2%. Approximately 61,727,211 shares of Parent Common Stock were issued and outstanding immediately following the merger, comprising approximately 31,831,595 shares to Legacy Obsidian securityholders, 730,057 shares to Galera securityholders, and 29,165,559 shares to PIPE investors.

## Terms
- Counterparty: Obsidian Therapeutics, Inc. · Consideration: stock · Stake: 1.2%

## Key dates
- Announced 2026-06-02 · Record 2026-07-31 · Completed 2026-08-03

## Timeline
- 2026-06-02 · 425 (0001193125-26-253623): 425 - Galera Therapeutics, Inc. — *Galera Therapeutics, Inc. is a pharmaceutical company developing therapeutic candidates.* Galera Therapeutics, Inc. and Obsidian Therapeutics, Inc. have agreed to merge under a dual-merger structure with Gazelle Parent, Inc., pursuant to an Agreement and Plan of Merger dated April 14, 2026. Under the transaction, Galera will merge with and into Galera Merger Sub (a wholly owned subsidiary of Parent), with Galera surviving as a wholly owned subsidiary of Parent. Simultaneously, Obsidian will merge with and into Obsidian Merger Sub (also a wholly owned subsidiary of Parent), with Obsidian surviving as a wholly owned subsidiary of Parent. The transaction is subject to satisfaction or waiver of conditions set forth in the Merger Agreement.
  https://www.sec.gov/Archives/edgar/data/1563577/0001193125-26-253623.txt
- 2026-06-02 · 425 (0001193125-26-253624): 425 - Galera Therapeutics, Inc. — *Galera Therapeutics develops oncology therapeutics, including engineered cell therapies; the filing highlights Obsidian's OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 for advanced melanoma.* Galera Therapeutics and Obsidian Therapeutics agreed to merge under a parent holding company, Gazelle Parent, Inc., pursuant to an Agreement and Plan of Merger dated April 14, 2026. Under the transaction structure, Galera will merge with and into Gazelle Merger Subsidiary (Galera Merger Sub), and Obsidian will merge with and into Onyx MergerSub, with both companies surviving as wholly owned subsidiaries of Parent. The filing does not disclose the deal value, consideration type, or expected closing date.
  https://www.sec.gov/Archives/edgar/data/1563577/0001193125-26-253624.txt
- 2026-08-04 · 8-K (0001193125-26-331207): 8-K - Galera Therapeutics, Inc. — *Galera Therapeutics, Inc. is a biopharmaceutical company developing pharmaceutical products, including tilarganine-based products and supportive-care compounds GC4419 and GC4711.* On August 3, 2026, Galera Therapeutics, Inc. completed a merger with Obsidian Therapeutics, Inc. pursuant to an Agreement and Plan of Merger dated April 14, 2026. In the transaction, Obsidian Merger Sub merged with and into Legacy Obsidian (with Legacy Obsidian surviving), and immediately thereafter Galera Merger Sub merged with and into Galera (with Galera surviving). Both companies became wholly owned subsidiaries of Obsidian Therapeutics, Inc. (formerly Gazelle Parent, Inc.). Legacy Obsidian securityholders received shares at an exchange ratio of 0.1383 and owned approximately 51.6% of the combined company on a fully diluted basis; Galera securityholders received shares at an exchange ratio of 0.7019 and owned approximately 1.2%; and concurrent PIPE investors owned approximately 47.2%. Approximately 61,727,211 shares of Parent Common Stock were issued and outstanding immediately following the merger, comprising approximately 31,831,595 shares to Legacy Obsidian securityholders, 730,057 shares to Galera securityholders, and 29,165,559 shares to PIPE investors.
  https://www.sec.gov/Archives/edgar/data/1563577/0001193125-26-331207.txt

## Citations
- 0001193125-26-253623 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526253623
- 0001193125-26-253624 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526253624
- 0001193125-26-331207 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526331207